REMEGEN

09995

68.1003.13% ( -2.200 )

Delay Trading: Oct 13, 15:55:03

Weekly Recap | REMEGEN -2.56%, consensus target above spot
Weekly Review·Oct 10, 2026 at 05:56 AM
09995-2.77%
RemeGen falls 3% in Hong Kong as biopharma sector pulls back
HK Stock Market Update·Oct 7, 2026 at 01:37 AM
09995-2.77%
Small-Cap Liquidity Surge: Guarantees and Clinical Wins Drive Hong Kong Market Moves
Global Report·Oct 6, 2026 at 10:15 AM
01787+0.95%02208-2.63%
Weekly Recap | 9995.HK +2.39%, consensus target sits above spot
Weekly Review·Oct 3, 2026 at 06:08 AM
09995-2.77%
RemeGen falls 7% in Hong Kong trading
HK Stock Market Update·Oct 2, 2026 at 01:36 AM
09995-2.77%
RemeGen gains 1% in Hong Kong as biopharma sector rallies
HK Stock Market Update·Sep 29, 2026 at 01:36 AM
09995-2.77%
RemeGen Reshapes Company Secretariat and Hong Kong Representation Roles
Tip Ranks·Sep 28, 2026 at 09:10 AM
09995-2.77%688331-3.82%
Weekly Recap | REMEGEN -9.16%, near its range low
Weekly Review·Sep 26, 2026 at 05:56 AM
09995-2.77%
RemeGen tumbles 8% as Fed rate-hike fears hit innovative pharma
HK Stock Market Update·Sep 24, 2026 at 05:20 AM
09995-2.77%
RemeGen falls 3% in Hong Kong trading
HK Stock Market Update·Sep 24, 2026 at 01:37 AM
09995-2.77%
The Great Pivot: AI Tokens, Record Profits, and the Bizarre Reality of the 2026 Market
Global Report·Sep 22, 2026 at 10:13 AM
01788-0.52%01520+5.77%
Weekly Recap | REMEGEN -1.71%, consensus target sits above spot
Weekly Review·Sep 19, 2026 at 05:30 AM
09995-2.77%
UBS Sticks to Its Buy Rating for RemeGen Co. Ltd. Class H (9995)
Tip Ranks·Sep 18, 2026 at 12:25 AM
09995-2.77%688331-3.82%
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
prnewswire·Sep 16, 2026 at 02:32 PM
09995-2.77%688331-3.82%
The Shifting Narrative of China's Biotech Pipeline
Global Report·Sep 16, 2026 at 11:31 AM
00370-13.30%02216-1.60%